阿尔茨海默病的最新进展:从基础研究到诊断和治疗
Enjie Liu1, Yao Zhang2, Jian-Zhi Wang3,4,5
1Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Translational neurodegeneration
|September 5, 2024
概括
阿尔茨海默病的研究正在推进,重点关注风险因素,粉样β和病理,以及疫苗等新疗法. 了解这些机制是开发有效阿尔茨海默氏症疗法的关键.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种主要的神经退行性疾病,其特征是粉样β (Aβ) 斑块和高酸化 (pTau) .
- 阿尔茨海默病患者的认知能力下降是显著的,但潜在的分子机制和有效的治疗方法仍然难以捉摸.
- 目前的治疗方案无法阻止或逆转AD的进展.
研究的目的:
- 为提供对阿尔茨海默病研究的最新审查.
- 涵盖风险因素,病理机制,诊断策略和治疗进展.
- 巩固当前的知识,从基本机制到临床应用.
主要方法:
- 文献综述和综合阿尔茨海默病研究中的最新发现.
- 分析风险因素 (例如,APOE变体,炎症) 和它们在AD病变发生过程中的作用.
- 实验模型,诊断工具,生物标志物和新兴疗法的总结.
主要成果:
- 更新了对风险因素如何导致AD中的Aβ和tau病理的理解.
- 目前的诊断和预测策略的概述,包括外围生物标志物.
- 审查疾病修饰药物的开发,包括Aβ疫苗和pTau向疗法.
结论:
- 在了解AD机制和开发潜在治疗方面取得了重大进展.
- 针对Aβ和pTau的新治疗策略显示了未来AD管理的前景.
- 持续的研究对于开发有效的干预措施来对抗阿尔茨海默病至关重要.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.9K
07:57An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices
Published on: April 11, 2018
6.9K
相关概念视频
Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Dementia
107
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
107
Parkinson's Disease: Overview
499
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
499
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
